Editas Medicine, Inc.: receives approval to initiate first-in-human trial of EDIT-401

What happened Editas Medicine, Inc. announced on Oct 8, 2026 that it received approval to initiate the Phase 1/2 Strive clinical trial of EDIT-401 in patients with heterozygous familial hypercholesterolemia in Australia. The filing said the trial received Human Research Ethics Committee approval, completed the Clinical Trial Notification process with Australia’s Therapeutic Goods Administration, and has been submitted for review in New Zealand; if approved in New Zealand, patients in both countries will be eligible to enroll.

The filing describes EDIT-401 as an experimental in vivo gene editing medicine designed to edit the LDL receptor (LDLR) gene to increase LDLR protein expression and reduce LDL-cholesterol (LDL-C). In preclinical studies in non-human primates, EDIT-401 demonstrated approximately 90% or greater mean reduction in multiple atherogenic lipoproteins, including LDL-C, lipoprotein(a) (Lp(a)), and apolipoprotein B (ApoB), and an LDL-C reduction of approximately 90% was maintained over 10 months in an ongoing study.

Key details

• Trial: Phase 1/2 Strive designed to evaluate safety, tolerability, and efficacy of a single dose of EDIT-401.
• Design: Part 1 is a single ascending dose, dose-finding, open-label trial; Part 2 will be a single-dose randomized, placebo-controlled expansion study.
• Sites and timing: Company selected 5 clinical trial sites across Australia and New Zealand; expects to report initial safety and tolerability data in the first quarter of 2027 and to complete enrollment in Part 1 with topline results later in 2027.
• Preclinical results: approximately 90% or greater mean reductions in LDL-C, Lp(a), and ApoB in non-human primates; ~90% LDL-C reduction maintained over 10 months in an ongoing study.

Why it may matter The filing reports Item 7.01 (regulation FD disclosure) and Item 8.01 (other events) and covers the company’s announcement that it received regulatory and ethics approvals to begin a first-in-human trial of EDIT-401, the trial design, site selection, timing for initial data, and preclinical efficacy data. This filing does not show why the insider traded or why the company acted.